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The Effect of Ginkgo Biloba on Alzheimer's Disease
Abstract. Alzheimer's disease is a progressive dementia associated with increasing loss of
memory, intellectual function, and disturbances in speech. It is the most common form of
dementia. It is an incurable disease and has four stages which culminate in coma and death. The
average survival rate for Alzheimer's is seven years. Presently, the only treatments approved in
the United States for Alzheimer's are the drugs tacrine and donepezil. These drugs improve
cognitive function in early Alzheimer's. However, Ginkgo biloba has recently been looked at as
another treatment option and has been approved for use in Germany. Ginkgo Biloba was
originally used in China and has recently become popular in the western world. It claims to
improve cerebral insufficiency, hearing impairment, circulation to the extremities, and memory in
early Alzheimer's disease. The side effects of Ginkgo include reduced blood clotting; restlessness,
diarrhea, nausea, headache, dizziness, and heart palpitations in less than four percent of people;
and it isn't recommended for pregnant or lactating women Several studies have been conducted
to investigate the effects of ginkgo biloba. These studies found a protective effect against free
radical damage, a beneficial effect on neural cells, and similar effects of ginkgo when compared to
tacrine. Despite the positive findings for ginkgo biloba in these studies, it is limited by only having
benefit in the early stages of Alzheimer's disease. The findings for ginkgo biloba support its use
in early Alzheimer's, but more research needs to be done before it can be recommended for
treatment in the United States.
Introduction
One of our greatest fears as a people is losing mental capacity as we age. Loss of mental
capacity is more commonly called dementia, and the most common form of dementia in the
United States today is Alzheimer's disease. This progressive dementia is named after Alois
Alzheimer, who first described the clinical findings related to it, and it affects fifteen million
people worldwide(S). The Merck Manual of Diagnosis and Therapy defines Alzheimer's disease
as "A progressive, inexorable loss of cognitive function associated with an excessive number of
senile plaques in the cerebral cortex and subcortical gray matter, which also contains beta amyloid
and neurofibrillary tangles consisting of tau protein. "(p 1395-6) Patients afflicted with
Alzheimer's have a progressive loss of memory, intellectual function, and increasing speech
disturbances. Incidence increases as age increases, with most cases appearing after the age of

sixty(2). There is no known cause of Alzheimer's disease, although there is thought to be a
common genetic factor(5). Risk factors commonly associated with Alzheimer's disease include
birth order, head injury, level of education, and presence of Down's syndrome(5).

Stages of Alzheimer's
Alzheimer's disease presents itself in four stages. The first stage is called the early stage,
and is characterized by loss of recent memory, inability to learn and retain new information,
language problems, mood swings, and personality changes(2). Language problems generally
include anomia (forgetting names of objects), echolalia (repeating words spoken by others), and
agnosia (loss of comprehension)(5).

In the early stage sociability isn't lost, but families may

report strange behavior. The next stage is called the intermediate stage, and it is characterized by
loss of long-term or remote memory, assistance required for basic activities such as bathing and
toileting, and behavioral disorganization such as wandering, agitation, hostility,
uncooperativeness, and physical aggression(2). By this point patients have lost all sense of time
and place and get lost and confused easily. The next stage of Alzheimer's is the severe stage. By
this stage, patients have lost all memory, cannot walk, eat or perform any activity of daily living.
Patients become at risk for pneumonia, malnutrition, and pressure sores and often must be placed
in a long-term care facility(2). The patient eventually becomes mute and proceeds to the end
stage of Alzheimer's, which is characterized by coma and death(2).

Current and Potential Treatments
The current treatment for Alzheimer's in the United States is limited to tacrine and
donepezil, two drugs that are supposed to improve memory in the early stage of Alzheimer's
disease(4). However, a new treatment may be up for consideration. In 1994, a new treatment
was approved in Germany. This treatment is SeGb, an extract of the Ginkgo Biloba tree(4).

Extracts of this tree's leaves have been used in China for various conditions since 2800 BC. It
has only recently become popular in the western world(3).
Ginkgo has a variety of health claims associated with its use. It is supposed to reduce
cerebral insufficiency (forgetfulness, dizziness, concentration difficulties, memory impairment,
depression, anxiety), reduce tinnitus and other hearing impairment, improve circulation to the
extremities, and improve memory in early Alzheimer's disease or other multi-infarct dementia(3).
It is this last claim which has recently been the subject of several studies involving tests of Ginkgo

Biloba extract. In the following studies a standardized extract of Ginkgo containing 24%
flavonoid glycosides and 6% terpenoids was used. This extract will be referred to as EGb 761(1).
In a study comparing EGb 761 to tacrine in patients with light to moderate dementia, EGb
761 patients showed similar central nervous system improvements as those patients using tacrine.
The patients were evaluated using computer-analyzed electrical activity of the brain. 240 mg of
EGb 761 were used in treating the dementia patients in comparison with 40 mg oftacrine(4).
Another study, this one a randomized controlled trial, administered EGb 761 to 75
patients with early Alzheimer's disease at 120 mg per day and gave 75 Alzheii:ner's patients a
placebo(6). This study lasted for one year. The patients that were given EGb 761 had
significantly higher scores on two cognitive tests - the Alzheimer's Disease Assessment ScaleCognitive Subscale (ADAD-Cog) and the Geriatric Evaluation by Relative's Rating Instrument.
The first test measures cognitive function and the second measures daily living and social
behavior(6). This study would seem to suggest a possible benefit of ginkgo extract in early
Alzheimer's and suggests further investigation.
Another, more scientific study looked into the mechanisms of ginkgo biloba extract on the
cells of the brain. This study, conducted in 2001, involved administering EGb 761 to mice, then

looking at the genes that were affected by the herb(9). The study found that EGb 761 upregulated several genes that neuroprotective roles. One of these was the gene that encodes
transthyretin, which is a hormone that has been found in low levels in Alzheimer's disease
patients(9). The ginkgo extract also enhanced the function of many other genes that are
important in neural function. This would seem to contribute to the theory that Ginkgo enhances
cognitive function.
One last study took a look at the individual components ofEGb 761, namely the flavonoid
component that makes up 24% of standardized Ginkgo Biloba(l). Many studies have shown that
ginkgo biloba is a free radical scavenger. Free radicals are highly reactive oxygen species that can
cause damage to unsaturated membrane phospholipids(S). The brain, being high in these
unsaturated phospholipids, is especially susceptible to oxidative damage(S). This study found that
the flavonoid component of ginkgo biloba scavenges free radicals; in this case, the free radical
Nitric Oxide( 1). This scavenging effect protected and rescued hippocampal neuronal cells,
supporting the use of ginkgo extract in cerebral insufficiency( l ). This protective effect may even
suggest a use for ginkgo in prevention of neural damage as well as treatment.
Despite this evidence supporting the use of Ginkgo Biloba extract in treatment of early
Alzheimer's and other dementias, there are differing opinions. In 1996, Dr. Russell G. Robertson
conducted a literature review of ginkgo biloba, and stated that while he believed that there were
no harmful effects of ginkgo use at low levels, there were also no beneficial effects(?).
Compared to many medicinal treatments, ginkgo biloba has few adverse side effects. It is
a blood thinner, and should not be used with Coumadin or any other anti-clotting therapy(3). In
less than four percent of individuals taking ginkgo biloba, side effects like restlessness, diarrhea,
nausea, headache, dizziness, and heart palpitations were reported(3). Ginkgo biloba is also not

recommended for pregnant or lactating women, and individuals have reported severe allergic
reactions from eating the fruit and seeds of the Ginkgo tree(3). There has also been concern
about ginkgo biloba, along with other herbal treatments, contributing to infertility; however, in the
treatment of Alzheimer's disease this would not be an issue of concern(8).
Ginkgo biloba is not a miracle drug, nor does it do anything above and beyond the
treatments that are already prescribed for early Alzheimer's disease and dementia. It is also
limited by only being of use in the early stage of Alzheimer's disease. Once patients have
progressed beyond this stage, the herb has not been found to have any beneficial effect. Also,
ginkgo biloba can only relieve symptoms of the disease; it can do nothing to reverse or halt the
progression of the disease itself Alzheimer's disease is incurable(5) and cannot be reversed by
any known treatment. Besides that, not every ginkgo biloba on the market will provide the same
effect. There are more than twenty-four different brands of ginkgo biloba sold in the United
States( 4). The only ones that will provide the effect produced in ginkgo biloba studies are the
standardized extracts containing 24% flavonoids and 6% terpenoids. Lastly, the study of ginkgo
biloba's effect on Alzheimer's disease is still in the early stages, and more testing is required to
verify the benefit of ginkgo biloba treatment.

Conclusions
Alzheimer's disease is a progressive, debilitating dementia that robs it's victims of their
memory, personality, and eventually, their life. In the investigations for treatment of this disease,
ginkgo biloba has been shown preliminarily to have some beneficial effect in relieving early
symptoms and prolonging progressive of the dementia for a short while. While further testing
needs to be done before gingko can be approved for treatment, it has shown promise in alleviating
the symptoms of early Alzheimer's disease.
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